Key clinical point: Cardiovascular (CV) adverse events were common with proteasome inhibitor therapy for relapsed multiple myeloma, particularly with carfilzomib.
Major finding: CV adverse events were reported in 16.7% of patients treated with bortezomib and 50.7% of patients treated with carfilzomib (P = .005).
Study details: A prospective, observational study of 95 patients with relapsed multiple myeloma who received proteasome inhibitors over a period of 18 months.
Disclosures: Some authors reported financial relationships with carfilzomib maker Amgen and bortezomib maker Takeda, as well as with other companies.
Cornell RF et al. J Clin Oncol. 2019 Jun 12. doi: 10.1200/JCO.19.00231.